Goldsmith K L, Mourant A E, Bangham D R
Bull World Health Organ. 1967;36(3):435-45.
Some time ago the WHO Expert Committee on Biological Standardization asked the National Institute for Medical Research, London, to consult with the WHO International Blood Group Reference Laboratory concerning the establishment of an international standard for albumin-potentiated anti-Rh(o) (anti-D) blood-typing serum. This paper describes the collection and testing of sera, the removal of unwanted antibodies, the pooling of the sera and the distribution in equal amounts in 3350 ampoules, which were subsequently freeze-dried. The titres were determined by 29 laboratories in 21 countries by means of four methods-suspension in albumin, replacement with albumin, enzyme (papain) treatment and the anti-human-globulin test. On the basis of the results obtained, the material has been established as the International Standard for Anti-Rh(o) (Anti-D) Incomplete Blood-Typing Serum and the International Unit has been defined, with the agreement of the participants in the collaborative study, as the activity contained in 0.95 mg of the International Standard for Anti-Rh(o) (Anti-D) Incomplete Blood-Typing Serum.
不久前，世界卫生组织生物标准化专家委员会要求伦敦的国家医学研究所就建立白蛋白增强抗 - Rh(o)（抗 - D）血型血清国际标准一事与世界卫生组织国际血型参考实验室进行磋商。本文描述了血清的收集与检测、去除不需要的抗体、血清的合并以及将其等量分装于3350支安瓿瓶中，随后进行冻干处理的过程。21个国家的29个实验室通过四种方法——白蛋白悬浮法、白蛋白替代法、酶（木瓜蛋白酶）处理法和抗人球蛋白试验——测定了效价。根据所获得的结果，该物质已被确立为抗 - Rh(o)（抗 - D）不完全血型血清国际标准，并且在协作研究参与者的一致同意下，国际单位被定义为0.95毫克抗 - Rh(o)（抗 - D）不完全血型血清国际标准中所含的活性。
